Introduction
. The secreted factor transforming growth factor ␤1
We have attempted to resolve the multiple, and some-(TGF␤1) has been proposed to play an important role times contradictory, roles of TGF␤1 in skin carcinogenein epithelial carcinogenesis, since it is known to be both sis in vivo using transgenic mice with keratinocytea potent negative epithelial cell growth regulator and a targeted expression of TGF␤1. Previously, long-term modulator of cellular phenotype (Roberts and Sporn, chemical carcinogenesis studies utilizing TGF␤1 keratin 1990; Alexandrow and Moses, 1995; promoter transgenic mice or TGF␤1 null animals have not 1996). Furthermore, TGF␤1 is induced in mouse epiderbeen possible because of the early death of these mis in response to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) (Akhurst et al., 1988 ; Krieg transgenic and knockout lines (Sellheyer et al., 1993; Fowlis et al., 1992) , and its expression is Glick et al., 1994) . We have recently generated and charoften elevated in tumor cells in vivo (Derynck et al., 1987;  acterized a number of keratin promoter TGF␤1 trans- Dickson et al., 1987; Gomella et al., 1989) . However, genic lines, which express recombinant TGF␤1 and are much controversy exists as to its exact contribution, if viable in the homozygous state (Cui et al., 1995 ; Fowlis any, to the outgrowth and phenotype of tumors in vivo. et al., 1996) . These have allowed us to examine the Loss of the growth response to TGF␤1 occurs in some influence of TGF␤1 on the induction and progression of human and mouse tumors (Terzaghi-Howe, 1989; Hadskin tumors in vivo. dow et al., 1991; Manning et al., 1991; Missero et al., The mouse skin model of multistage carcinogenesis 1991) and might contribute to tumor outgrowth. Indeed, is ideally suited to investigations of this kind, since it has genetic mutations in the TGF␤ type II receptor, T␤RII, been well characterized with respect to both phenotypic and genetic changes (Kemp et al., 1994; (DMBA). Repeated biweekly application of the tumor promoter, TPA, leads to the outgrowth of highly differentiated benign papillomas by around 15 weeks postinitiation. After a further 10-15 weeks, a small subset of papillomas eventually progress to malignant squamous carcinoma. Finally, a small portion of these carcinomas undergo an epithelial to mesenchymal transformation to the most malignant tumor type, the spindle cell carcinoma (Klein-Szanto et al., 1989; Buchmann et al., 1991) . The spindle cell, the most invasive, motile carcinoma cell type, has altered expression of keratinocyte-specific markers, such as cytokeratins, and loss of E-cadherin expression and is characterized by expression of fibroblastoid cell markers, such as vimentin (Stoler et al., 1993; Caulin et al., 1995) .
Here we show that TGF␤1 appears to have different functions at early and late stages of tumorigenesis. It acts as a suppressor of benign tumor outgrowth, but later accelerates malignant conversion and the squamous to spindle cell transformation. (Table 1). formed utilizing 10 control, 13 F line, and 7 H line mice (A); 12 control, Line H is transgenic for a construct driving constitutive 23 H line, 21 D line, and 11 M2 line mice (B) ; and 17 control and 21 M5 line mice (C). Within each experiment, DMBA treatment was expression of activated simian TGF␤1 (sTGF␤1 act ) in superformed on each animal at the same time, and each animal was prabasal keratinocytes of the skin, utilizing a bovine KVI subsequently treated identically. Tumor numbers were counted (corresponding to human keratin 10 [K10]) gene proeach week, and the cumulative average per mouse was plotted moter (Cui et al., 1995) . The M2 and M5 lines drive exversus weeks post-DMBA treatment. By 26 weeks, when the tumor pression of sTGF␤1 act in suprabasal keratinocytes, but numbers were reaching plateau, the average tumor number per utilize an inducible keratin gene promoter, KIV* (corremouse in the transgenics was reduced by up to 6-fold compared with controls (P values all < 0.05 using a Student's one-tailed t test).
Results

TGF␤1 Suppresses Benign Tumor Outgrowth In Vivo
sponding to human K6), which is only expressed in the However, it should be emphasized that this is a minimal estimate hyperplastic state, for example following topical appliof tumor suppression since, for reasons of humanity, several control cation of TPA or in hyperplastic keratinocytes of papillomice with very high benign tumor loads were prematurely removed mas and carcinomas (Fowlis et al., 1996) . The D and F from the study.
line mice are transgenic for the inducible K6 promoter driving expression of native, latent murine (m)TGF␤1 (Fowlis et al., 1996) . All five lines gave qualitatively simito malignant carcinoma. The benign tumor latency, of 8-9 weeks, was the same in both control and transgenic lar results in chemical carcinogenesis experiments, regardless of the gene promoter used or the nature of the groups (Figure 1 ). However, there was a consistent and significant reduction in the benign tumor number per encoded TGF␤1 protein, although the M2 line showed the most dramatic effects. mouse in the transgenic compared with the control group throughout 26 weeks of observation ( Figure 1 ). Three independent chemical carcinogenesis experiments were performed utilizing 135 mice from D, F, H, Suppression of benign tumor outgrowth was apparent as early as 9 weeks post-DMBA in the first experiment M2, and M5 lines and controls (Figure 1 ). Animals were initiated by a single treatment with DMBA, followed by and clear by 13 weeks post-DMBA in all three experiments. The effect was greatest in the M2 and D lines, tumor promotion by twice weekly application of TPA for 20 weeks. This treatment normally results in the outin which the benign tumor number per mouse at 26 weeks post-DMBA was reduced 6-fold compared with growth of benign tumors, a minority of which progress Following chemical carcinogenesis treatment, the appearance of the first carcinoma was noted for each mouse line. At the termination of the experiment (44 weeks post-DMBA), all carcinomas were enumerated, and histological analysis was performed. Carcinomas were scored as well-differentiated squamous carcinoma (grade I-II), poorly differentiated squamous carcinoma (grade III-IV), or aggressive spindle cell carcinomas. Note the reduced latency before carcinoma appearance and the prevalence of spindle cell carcinomas in the transgenic mice. Also note that the data in Table 2 were collected at the termination of the experiment (44 weeks post-DMBA), in contrast with the data in Figures 1 and 2 , which derived from observations at 26 weeks post-DMBA. a Cumulative carcinoma total at 44 weeks per cumulative papilloma total at 26 weeks.
the control group (Figure 1) . These data unequivocally demonstrate that, at early stages of chemical carcinogenesis, keratinocyte-derived TGF␤1 is not a tumor promoter, but suppresses benign tumor outgrowth, probably via its growth-inhibitory or differentiation-inducing effects on the initiated cell.
TGF␤1 Enhances Malignant Conversion Rate In Vivo
Despite the relative paucity of benign tumors on the transgenic mice, those tumors that did develop had a very high malignant conversion frequency, manifested as an earlier appearance of carcinoma (Table 2) and an absolute increase in the number of carcinomas per mouse relative to the control group ( Figure 2B ). At 26 weeks post-DMBA, none of the 532 control papillomas had progressed to carcinoma, contrasting with a malignant conversion frequency of 12.5% (5 of 40) for the M2 line and 7.8% (5 of 77) for the D line mice ( Figure 2A ).
In conclusion, although keratinocyte-derived TGF␤1 inhibited papilloma outgrowth, the papillomas that developed were at high risk for malignant conversion, resulting in an overall increase in malignant tumor number despite a reduction in total (benign plus malignant) tumor number.
TGF␤1 Stimulates the Squamous to Spindle Cell Transformation In Vivo
In addition to the increased malignant conversion frequency in transgenics compared with controls, there was a notable increase in the incidence of highly malignant spindle cell carcinomas in the transgenic mice. Indeed, at the termination of the experiment, after 44 weeks, over one third of carcinomas (8 of 21) from transgenic mice expressing sTGF␤1 act were highly malig- (1 of 8) for control carcinomas (Table 2 ). This is in spite
Mice were subjected to chemical carcinogenesis treatment, and 26 weeks post-DMBA the total papilloma and carcinoma numbers were of the fact that the average papilloma number was sub- transgene is constitutively expressed, at low levels, in suprabasal keratinocytes (Cui et al., 1995) and that the Nelson and Slaga, 1982; Toftgard et al., 1985; . Expression of the K10 transgene (H line) was K6 transgenes are expressed in hyperplastic suprabasal keratinocytes after TPA treatment (Fowlis et al., 1996) .
considerably reduced in papillomas and carcinomas compared with normal skin (data not shown). In contrast, The increase in malignant conversion frequency seen in the transgenic animals could be attributed to an early K6-derived transcripts were expressed at very high levels in suprabasal keratinocytes of papillomas and wellselection for a high risk papilloma subtype during the tumor promotion phase (Hennings et al., 1985) and/or to differentiated carcinomas and in isolated suprabasal cells of poorly differentiated squamous carcinomas (Figpersistent overexpression of recombinant TGF␤1 within the papillomas, directly modulating the tumor phenoures 3A-3D). The spindle cell carcinomas no longer expressed either transgene ( Figures 3E-3F ). type. It was therefore important to determine whether or not recombinant TGF␤1 was expressed in the benign Determination of recombinant TGF␤1 protein expression was more problematic, as previously reported by papillomas. In situ hybridization analysis with a transgene-specific probe showed that the transgenes beourselves and others (Sellheyer et al., 1993; Cui et al., 1995) . Immunohistochemistry utilizing two anti-TGF␤1 haved in a manner expected from the endogenous expression profiles of K10 and K6 (Winter et al., 1980;  antibodies (Flanders et al., 1989) showed no quantitative difference in TGF␤1 protein expression between carcinomas (including transgenics and controls) to in situ hybridization utilizing isoform-specific probes for transgenic and control tumors. However, a third antibody (anti-pre-266-278-1) against the latency-associ-TGF␤1, TGF␤2, and TGF␤3 (Fitzpatrick et al., 1990) . Additionally, 5 spindle cell carcinomas were subjected to ated peptide (Wakefield et al., 1990) , though variable, was more intense in transgenic papillomas compared immunohistochemical analysis with the anti-pre-266-278-1 antibody. The most striking observation was that with controls (Figure 4) , supporting the hypothesis that continued expression of the transgene, at least through TGF␤3 RNA levels were elevated during tumor progression. Papillomas expressed very low to undetectable the benign tumor stage, could contribute to the increased malignant conversion frequency. levels of TGF␤3 RNA (data not shown), and there was slightly elevated TGF␤3 expression in some well-differentiated carcinomas within the basal keratinocyte layer Endogenous TGF␤3, TGF␤1, or Both Are Up-Regulated in Spindle ( Figures 3G and 3H ). TGF␤3 expression was elevated further in poorly differentiated squamous carcinomas Cell Carcinomas If TGF␤1 drives the spindle cell conversion, extinction ( Figures 3G and 3H ) and persisted at very high levels in 6 out of the 7 spindle cell carcinomas examined (Figures of transgene expression within the spindle tumors per se ( Figures 3E and 3F ) suggests either that TGF␤ is 3I and 3J). The one exceptional spindle cell carcinoma that expressed only low levels of TGF␤3 had high levels required for the conversion event, but not for maintenance of the spindle phenotype, or that endogenous of endogenous TGF␤1 expression (data not shown). Endogenous TGF␤1 RNA and protein were detectable in TGF␤(s) might fulfill the function of maintenance of the spindle phenotype. To address this issue, we subjected some, but not all, spindle cell carcinomas (data not shown). It is therefore apparent that there is a strong 6 papillomas, 7 squamous carcinomas, and 7 spindle increase in TGF␤3 expression during multistage carciet al., 1996) . However, this keratin is only transiently expressed in papillomas, as the protein is down-regunogenesis and that this growth factor could be involved in maintenance of the spindle cell phenotype. lated as keratinocytes progress to malignancy. Cano et al. (1996) reported two types of K13 expression, a heterogeneous pattern, associated with a higher risk TGF␤1 Transgenic Papillomas Have a More of malignant conversion, and a homogeneous pattern, Dysplastic Phenotype, with Altered K13 associated with a lower risk for malignant conversion.
and Integrin Expression
In the present study, all tumors showed K13 expression, TGF␤1 might enhance malignant conversion frequency and homogeneous ( Figures 5A and 5C ) and heterogein a number of ways, including evasion of host immune neous ( Figures 5B and 5D ) patterns were seen in both surveillance, either locally or systemically (Torre-Amione control and transgenic tumors. However, in the M2 line, et al., 1990; Arteaga et al., 1990 ), enhancement of angiowhich showed the largest transgene effect in terms of genesis (Roberts et al., 1986) , 1995) . To investigate the mechanism(s) whereby vealed an increased incidence of small dysplastic foci recombinant TGF␤1 enhanced the malignant conversion within the transgenic papillomas. Again, this was most frequency and phenotype, we examined the transgenic apparent in the M2 line. These dysplastic foci were charpapillomas for alterations in a number of histological acterized by elevated ubiquitous membranous ␣2 inteparameters.
grin expression ( Figure 5I ), delocalized expression of ␣6 A number of studies have correlated changes in the and ␤4 integrin ( Figure 5G) , and heterogeneous or abexpression patterns of K13, E-cadherin, and ␣6␤4 intesent staining for K13 ( Figures 5B and 5D ). Whereas only grin with an altered risk for malignant conversion (Nischt 2 of 11 control papillomas contained these ␣2 integrinet Gomez et al., 1992; Tennenbaum et al., 1992, positive foci, 5 of 6 M2 papillomas had these dysplasias. 1993; Cano et al., 1996) . Furthermore, TGF␤1 has been Interestingly, the dysplastic foci were still E-cadherin reported to up-regulate expression of ␣1, ␣2, and ␣5 positive (data not shown). integrin, leading to enhanced tumor cell adhesion and Staining patterns for E-cadherin and ␣5 integrin were survival (Heino and Massague, 1989; Arrick et al., 1992;  identical in controls and transgenic papillomas, with the Chakrabarty, 1992; Chang et al., 1993; Wang et al., 1995) .
anti-E-cadherin antibody showing ubiquitous memWe therefore examined expression of ␣2, ␣5, ␣6, and brane staining of suprabasal and occasionally basal ker-␤4 integrins, E-cadherin, and K13 in aged-matched papatinocytes (data not shown) and the anti-␣5 integrin antiillomas of D, H, M2, M5, and control mice. The transgenic body showing predominant staining of the basal lamina and control tumors were histologically very similar, but (data not shown). In the nondysplastic areas of transthe immunohistochemical studies revealed a number of genic and control tumors, ␣2 integrin was restricted to subtle differences between the two tumor groups. These basal keratinocytes, particularly the basal lamina (Figdifferences were most marked when comparing M2 with ure 4). control tumors.
The TGF␤1 transgene clearly had an effect on the It has been reported that in high risk tumors the docellular phenotype of the papillomas, characterized by main of expression of ␣6␤4 integrin is extended from altered integrin and K13 expression. In contrast, examibeing predominantly basal to include suprabasal cells nation of the nuclear labeling indices for bromodeoxyuri- (Gomez et al., 1992; Tennenbaum et al., 1993; dine and estimation of the fraction of tumor cells underet al., 1996) . In the current study, both transgenic and going apoptosis, as assessed using an in situ end nontransgenic papillomas showed basal and suprabasal labeling approach (Ansari et al., 1993) , revealed no clear staining with the anti-␣6 antibody (data not shown).
differences between transgenics and controls (data not However, throughout the whole tumor, there was a difshown), suggesting no remarkable effect of TGF␤1 on ference in both the staining intensity and cellular staining cellular proliferation or turnover within the papillomas. pattern with the anti-␤4 antibody (Figures 5E-5G) . The transgenic papillomas generally showed more intense ␤4 staining than controls. Furthermore, whereas control Discussion tumors (n ϭ 11) showed predominantly basal ␤4 staining ( Figure 5E ), the transgenic tumors (n ϭ 17) had an ex-TGF␤1 in Early Tumor Growth A number of studies have addressed the role of TGF␤1 panded domain of ␤4 staining into the upper suprabasal layers ( Figure 5F ). This was true for all the transgenic in epithelial tumor promotion (Akhurst et al., 1988; Furstenberger et al., 1989; Pierce et al., 1995) . Previlines examined.
K13 is not expressed in normal keratinocytes, but ously, intracutaneous injection of TGF␤1, combined with treatment by non-tumor-promoting hyperplasiogenic is switched on in papillomas (Nischt et al., 1988) . Its expression has been associated with a high risk for agents, suggested that TGF␤1 is itself a tumor promoter (Furstenberger et al., 1989) . However, the present study malignant progression ; Cano definitively demonstrates the converse; that is, keratinoIn contrast with the above reports, and consistent with our present findings, a number of studies have cyte-derived TGF␤1 inhibits benign tumor outgrowth. This would complement the recent findings that TGF␤1 demonstrated that TGF␤1 gene expression constructs transfected into tumor cell lines in vitro enhance the is a suppressor of mammary tumorigenesis in vivo in mouse mammary tumor virus-TGF␤1 transgenic mice malignant properties of the resultant tumors in vivo (Welch et al., 1990; Torre-Amione et al., 1990; Arrick et (Pierce et al., 1995) . In the skin model, it is most likely that endogenous TGF␤1, induced in normal epidermis al., 1992; Steiner and Barrack, 1992; Arteaga et al., 1993a Arteaga et al., , 1993b Chang et al., 1993) . Indeed, in one study, in response to hyperplasia (Akhurst et al., 1988) , is a regulator of epidermal homeostasis (Cui et al., 1995) . At TGF␤1 overexpression led to an increased tumor mitotic index in vivo, despite the fact that the tumor cells rethe early tumor promotion stages of carcinogenesis, the predominant action of transgenic TGF␤1 is on keratinotained negative growth sensitivity to TGF␤1 in vitro, suggesting that the tumor-enhancing properties of TGF␤1 cyte growth inhibition (Haddow et al., 1991; Cui et al., 1995; Fowlis et al., 1996) , thus reducing the outgrowth predominated over negative growth regulation in vivo (Chang et al., 1993) . of benign tumors.
It is difficult to reconcile all these seemingly contradictory observations because of the diversity of cell lines TGF␤1 and Malignant Progression The role of TGF␤1 in malignant progression has been and experimental approaches taken. However, the results described in this report help to resolve these apparcontroversial. Previous functional studies to address the role of TGF␤1 in skin carcinogenesis have been limited ent contradictions, since we have analyzed the functions of TGF␤ at different steps of multistage carcinogenesis by the use of gene-transfected cultured tumor cells, which were subsequently injected or grafted in vivo in vivo, in a single epithelial cell system. The well-documented negative regulatory effects of TGF␤ on growth to generate tumors, and different experimental approaches have led to divergent conclusions. The use of control of epithelial cells (Terzaghi-Howe, 1989; Haddow et al., 1991; Manning et al., 1991; Missero et al., 1991 ) keratin promoter TGF␤1 transgenic mice has allowed us to address this problem directly, with the minimum would account for inhibition of benign tumor outgrowth seen in the current study. Clearly, this type of mechaof experimental intervention, by examination of the de novo induction of skin tumors in vivo. Our data clearly nism could lead to the outgrowth of cells that have acquired growth resistance through genetic alterations show that TGF␤1 enhances malignant progression rate and phenotype.
in TGF␤ signaling, which in turn might lead to increased proliferation and a higher probability of subsequent mu-A number of earlier studies showed that treatment with TGF␤1 antibodies or transfection of antisense tations that increase malignancy (Garrigue-Antar et al., 1995; Markowitz et al., 1995) . On the other hand, tumor TGF␤1 gene expression constructs into malignant cells in vitro enhanced the tumorigenicity of these cells after cells that evade negative growth regulation but retain other aspects of TGF␤ cell signaling (Chen et al., 1993 ) injection into athymic mice in vivo (Arteaga et al., 1990; Wu et al., 1992 Wu et al., , 1993 . Supporting this evidence, and could have greater malignant capacity through their ability to undergo a TGF␤-mediated switch to an invasive thus the proposal that TGF␤1 predominantly protects from malignant progression, is the observation that mesenchymal cell type (Miettinen et al., 1994; Caulin et al., 1995; Portella et al., submitted) . transfection with a T␤RII-expressing gene construct diminished tumorigenicity (Sun et al., 1994) . It has also been shown that TGF␤1 null keratinocytes, transduced TGF␤1 and the Epithelial-Mesenchymal Transition with mutant v-ras Ha in vitro and grafted onto athymic The high incidence of malignant fibroblastoid spindle mice, produced tumors with an enhanced malignant cell carcinomas in the transgenic mice is a particularly conversion rate and malignant character compared interesting observation. The ability of TGF␤ to induce with wild-type keratinocytes (Glick et al., 1994) . Furtherepithelial-mesenchymal transitions in embryonic cells in more, immunohistochemical examination of endogevitro has been reported utilizing the Xenopus mesoderm nous TGF␤1 expression levels in tumors in vivo has induction assay (Kimelman and Kirschner, 1987) and also supported the view that TGF␤1 can protect from an assay for transformation of chick endocardial cells malignant conversion. Elevation of TGF␤1 expression (Potts and Runyan, 1989) . It is also interesting that TGF␤ has been associated with mammary tumor regression isoform expression during embryogenesis is often asso- , and we and others have shown that ciated with sites of epithelial-mesenchymal transformalack of TGF␤1 expression in TGF␤1 growth-sensitive tion, such as during cardiogenesis and palatogenesis papillomas is predictive of a high rate of conversion to Fitzpatrick et al., 1990 ; Pelton et squamous carcinoma (Glick et al., 1993; Cui et al., 1994 Cui et al., ). al., 1990 Millan et al., 1991) . Furthermore, homozygous However, in all the above studies, TGF␤1 was clearly TGF␤3 knockout mice are specifically defective in still acting as a potent suppressor of keratinocyte prolifpalatal shelf fusion, which involves epithelial migration eration (Arteaga et al., 1990; Wu et al., 1992 Wu et al., , 1993 an epithelial-mesenchymal transformation event, et al., 1993, 1994; Cui et al., 1994; Sun et al., 1994) . among other biological processes (Kaartinen et al., In the current study, the effects of TGF␤1 on cellular 1995; Proetzel et al., 1995) . It is likely that TGF␤ synerphenotype seem to have outweighed its effects as an gizes with mitogenic growth factors in eliciting these inhibitor of keratinocyte proliferation at the benign tumor changes in epithelial plasticity (Anzano et al., 1982 ; Kistage, since there were no clear differences in cellular melman and Kirschner, 1987; Dixon et al., 1991; Jouanproliferation (Whitman and Melton, 1992; Umbhauer et al., 1995 Dlugosz et al., 1995) . an important mechanism during tumor invasion and mewhich was around 44 weeks post-DMBA. Each mouse was injected tastasis (Valles et al., 1991; Jouanneau et al., 1991b;  intraperitoneally with 50 g of bromodeoxyuridine per gram of body weight 1 hr before sacrifice. The tumors were snap-frozen in liquid Mareel et al., 1993; G. Portella et al., unpublished data) .
nitrogen and/or fixed overnight in freshly prepared 4% paraformal-TGF␤1 can directly stimulate epithelial-mesenchymal dehyde, followed by paraffin-embedding. Tumors were scored as transitions in cultured keratinocytes (Caulin et al., 1995;  carcinomas or papillomas by morphological appearance upon col-G. Portella et al., unpublished data) and mammary epilection of the tumor. The tumors were further histologically graded thelial cells (Miettinen et al., 1994) both in vitro and after after hematoxylin and eosin staining of paraffin sections.
injection into nude mice in vivo. This effect of TGF␤1 in
In Situ Hybridization enhancing the spindle cell conversion is certainly a diParaffin sections (5 m) were subjected to in situ hybridization using rect effect on the keratinocyte, rather than being sec- (Cui et al., 1995), D, E, M2, and M5 (Fowlis et al., 1996) transgenic lines has been previously Received February 19, 1996; revised July 8, 1996 . reported. Line H is transgenic for a construct driving constitutive expression of sTGF␤1 act in suprabasal keratinocytes of the skin, References utilizing a bovine KVI (K10) gene promoter. The M2 and M5 lines drive expression of sTGF␤1 act in suprabasal keratinocytes, utilizing Akhurst, R.J., Fee, F., and Balmain, A. (1988) . Localized production an inducible keratin gene promoter, KIV* (K6), and the D and F of TGF-␤ mRNA in tumour promoter-stimulated mouse epidermis. Nature 331, 363-365. lines mice were transgenic for the inducible K6 promoter driving
